Glofitamab, a CD20xCD3 bispecific antibody, when used with GemOx chemotherapy, improves survival in patients with R/R DLBCL compared with standard care.
Glofitamab, a fixed-duration CD20xCD3 bispecific antibody, combined with a chemotherapy regimen of gemcitabine and oxaliplatin , shows significant survival benefits in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma , compared with the standard-of-care regimen.
At a median follow-up of 21 months, those treated with glofitamab combined with GemOx had a significantly higher median overall survival of 25.5 months, compared with those treated with the standard of care of rituximab and GemOx in the United States, is an aggressive blood cancer. The standard second-line therapy is high-dose chemotherapy followed by ASCT.
Patients were randomized 2:1 either to treatment with glofitamab combined with GemOx, involving 8 cycles, in addition to 4 cycles of glofitamab monotherapy , or to the rituximab plus GemOx regimen in 8 cycles . CRS was the most frequently reported AE in the glofitamab group , and events consistent with immune effector cell–associated neurotoxicity syndrome were reported in four patients , all of which were concurrent with CRS."We found that with glofitamab GemOx, the toxicities were manageable, and the most common toxicity of CRS was predominantly low-grade and occurred with step-up dosing in cycle one and was completely reversible," Dr Abramson said.
"What I would say is a rising tide lifts all boats," he responded."It's great to have multiple effective immunotherapy strategies." "Further trials are needed in a broader large B-cell lymphoma population as this trial was limited to DLBCL not otherwise specified, so did not include patients with transformed lymphoma, primary mediastinal B-cell lymphoma, high grade B-cell lymphoma, etc."Commenting on the findings, Jonathan W.
Non-Hodgkin Lymphoma NHL Biologic Therapy Biologics Chimeric Antigen Receptor T-Cell Therapy Chimeric Antigen Receptors Chimeric Immunoreceptors Chimeric T-Cell Receptors Artificial T-Cell Receptors CAR T Chimaeric Antigen Receptor T-Cell Therapy Chimaeric Antigen Receptors Chimaeric Immunoreceptors Chimaeric T-Cell Receptors Chemotherapy
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Motorola Razr Plus (2024) vs Razr Plus (2023): Expected upgradesAleksandar is a tech enthusiast with a broad range of interests, from smartphones to space exploration. His curiosity extends to hands-on DIY experiments with his gadgets, and he enjoys switching between different brands to experience the latest innovations.
Read more »
iPhone 16 Plus vs iPhone 14 Plus: Is it time to upgrade?Mariyan, a tech enthusiast with a background in Nuclear Physics and Journalism, brings a unique perspective to PhoneArena. His childhood curiosity for gadgets evolved into a professional passion for technology, leading him to the role of Editor-in-Chief at PCWorld Bulgaria before joining PhoneArena.
Read more »
iPhone 16 Plus vs iPhone 15 Plus: ExpectationsMariyan, a tech enthusiast with a background in Nuclear Physics and Journalism, brings a unique perspective to PhoneArena. His childhood curiosity for gadgets evolved into a professional passion for technology, leading him to the role of Editor-in-Chief at PCWorld Bulgaria before joining PhoneArena.
Read more »
Michael Strahan Praises 'Superwoman' Daughter Isabella as She Completes Chemo for Brain TumorIsabella Strahan completed her chemotherapy treatment earlier this month after being diagnosed with brain cancer in October 2023.
Read more »
Michael Strahan Calls Daughter Isabella, 19, 'Superwoman' After Finishing Chemo for Brain Tumor: 'One Proud Dad'Michael Strahan shared an Instagram video of his 19-year-old daughter Isabella Strahan ringing the hospital bell after finishing chemotherapy for her brain tumor.
Read more »
Michael Strahan's Daughter Speaks Out After Finishing ChemoIsabella Strahan, who went public with her brain-cancer diagnosis in January, is celebrating the end of grueling treatments.
Read more »